(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 January 2020 (23.01.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/018975 A1

(51) International Patent Classification:
C07D 498/04 (2006.01) *C07D 413/06* (2006.01)
A61P 29/00 (2006.01) *A61K 31/4188* (2006.01)
A61P 35/00 (2006.01) *A61K 31/5365* (2006.01)
C07D 231/24 (2006.01) *A61K 31/415* (2006.01)

(21) International Application Number:
PCT/US2019/042711

(22) International Filing Date:
19 July 2019 (19.07.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/701,313 20 July 2018 (20.07.2018) US

(71) Applicant: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080 (US).

(72) Inventors: **MCBRIDE, Christopher**; c/o Jecure Therapeutics, Inc., 330 DNA Way, MS #49, South San Francisco, California 94080 (US). **TRZOSS, Lynnie Lin**; c/o Jecure Therapeutics, Inc., 330 DNA Way, MS #49, South San Francisco, California 94080 (US). **BOLOOR, Amogh**; c/o Jecure Therapeutics, Inc., 330 DNA Way, MS #49, South San Francisco, California 94080 (US). **SOKOLOVA, Nadezda**; c/o Jecure Therapeutics, Inc., 330 DNA Way, MS #49, South San Francisco, California 94080 (US). **PASTOR, Richard M.**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **STABEN, Steven Thomas**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **STIVALA, Craig**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **VOLGRAF, Matthew**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **BRONNER, Sarah M.**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US).

(74) Agent: **TIAN, Zong-Qiang Bill** et al.; c/o Genentech, Inc., 1 DNA Way, Mail Stop 49, South San Francisco, California 94080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2020/018975 A1

(54) Title: SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY



(I)

(57) Abstract: The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process. (I)